Search
Alglucosidase alfa
go.drugbank.com/drugs/DB01272ApprovedInvestigationalIt is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients. … It is encoded by the most predominant of nine observed haplotypes of this gene. Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line.
Products: (Alglucosidase alfa) 50mg Powder for Solution for InfusionColesevelam
go.drugbank.com/drugs/DB00930ApprovedInvestigationalIt works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.
Doxercalciferol
go.drugbank.com/drugs/DB06410ApprovedInvestigationalDoxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients
Liothyronine
go.drugbank.com/drugs/DB00279ApprovedInvestigationalVet approved[T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578]
Centanafadine
go.drugbank.com/drugs/DB14841ApprovedInvestigationalreuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment. … Centanafadine is a reuptake inhibitor at the norepinephrine, dopamine, and serotonin transporters and a central nervous system stimulant.
Ditiocarb zinc
go.drugbank.com/drugs/DB14193ApprovedDitiocarb zinc, also known as Diethyldithiocarbamic acid zinc salt, is a known chelator for copper and zinc. It also a dermatological sensitizer and allergen.
Ferric pyrophosphate citrate
go.drugbank.com/drugs/DB13995ApprovedFree iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma. … [L1419] It is also FDA approved since 2015.[FDA label]
Angiotensin II
go.drugbank.com/drugs/DB11842ApprovedInvestigationalThe novelty of the medication lies in the fact that it is the first and only use of synthetic human angiotensin II to help maintain body blood pressure. … As of December 21, 2017 the FDA approved La Jolla Pharmaceutical's Giapreza (angiotensin II) Injection for Intravenouse Infusion for the indication of acting as a vasoconstrictor to increase blood pressure
Damoctocog alfa pegol
go.drugbank.com/drugs/DB14700ApprovedInvestigational[L4576,A38909] This product has been engineered by Bayer[L4576] and a biological license application has been filed with the FDA in August 2017 and FDA approved in August 2018.[F1609] … In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized.
Solriamfetol
go.drugbank.com/drugs/DB14754ApprovedInvestigationalSolriamfetol was given FDA approval in 2019[FDA Label].